Sarepta raises full-year guidance

Sarepta Therapeutics Inc. (NASDAQ:SRPT) reported 2Q17 earnings and raised its full-year guidance for sales of Exondys 51 eteplirsen to $125-$130 million. Last quarter, it had guided for sales to "exceed $95 million" (see BioCentury Extra, April 27).

Sarepta announced the news after market close Wednesday, and was up $4.93 (14%) to $39.01 in after-hours trading...